

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application 10/522,426		Our File No. P/2107-264		
		Applicant Ferdinand Hermann Bahlmann, et al.				
		Filing Date March 25, 2006		Group Art Unit 1654		
<b>U.S. PATENT DOCUMENTS</b> (not submitted for applications filed after 6/30/03)						
Examiner Initial	Document Number	Date MM-YYYY	Name	Class	Sub- class	Filing Date If Appropriate
	US-5,980,887	11-1999	Isner et al.			
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
<b>FOREIGN PATENT DOCUMENTS</b>						
	Document Number	Date MM-YYYY	Country	Class	Sub- class	Translation Yes      No
	WO 89/07944	09-1989	WIPO/PCT			X
	WO 98/10650	03-1998	WIPO/PCT			X
	WO 00/61164	10-2000	WIPO/PCT			X
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Korean Office Action dated March 22, 2010 in corresponding Korean Patent Application No. 10-2005-7001341 (English language).				
		N. D. Vaziri, et al., "Erythropoietin Enhances Recovery From Cisplatin-Induced Acute Renal Failure," American Journal of Psysiology, Vol. 266, F360-F366 (1994).				
Examiner		Date Considered				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						